Burrouqhs Wellcome's Zovirax
This article was originally published in The Tan Sheet
Executive Summary
Advisory committee review of Rx-to-OTC switch for the anti- herpes agent acyclovir is tentatively scheduled for May 19. FDA's Antiviral Drugs and Nonprescription Drugs Advisory Committees had been slated to review the application in mid-February ("The Tan Sheet" Jan. 31, p. 1)
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning